SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Xilio Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

09/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- [x] Rule 13d-1(b)
- [ ] Rule 13d-1(c)
- [ ] Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons ADAR1 Capital Management, LLC	
2	Check the appropriate box if a member of a Group (see instructions) [ ] (a) [x] (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization TEXAS	
Number of Shares Beneficially	5	Sole Voting Power 0.00

Owned by Each Reporting Person With:	6	Shared Voting Power 381,000.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 381,000.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 381,000.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 9.3 %
12		Type of Reporting Person (See Instructions) IA, OO

Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 381,000 shares of common stock, par value $0.0001 per share ("Common Stock"), of Xilio Therapeutics, Inc. (the "Issuer") underlying pre-funded warrants and common warrants owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1"). Such securities may be deemed to be indirectly beneficially owned by ADAR1. Based on 3,702,072 shares of Common Stock of the Issuer outstanding as of September 30, 2025, reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 13, 2025. The number of shares outstanding and the number of shares held by ADAR1 are calculated with accounting for the 1-for-14 reverse stock split that occurred on March 13, 2026.

SCHEDULE 13G

CUSIP No.

1		Names of Reporting Persons Daniel Schneeberger
2		Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)
3		Sec Use Only
4		Citizenship or Place of Organization SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 381,000.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 381,000.00

9	Aggregate Amount Beneficially Owned by Each Reporting Person 381,000.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11	Percent of class represented by amount in row (9) 9.3 %
12	Type of Reporting Person (See Instructions) HC, IN

Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 381,000 shares of common stock, par value $0.0001 per share ("Common Stock"), of Xilio Therapeutics, Inc. (the "Issuer") underlying pre-funded warrants and common warrants owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1"). Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. Based on 3,702,072 shares of Common Stock of the Issuer outstanding as of September 30, 2025, reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 13, 2025. The number of shares outstanding and the number of shares held by ADAR1 are calculated with accounting for the 1-for-14 reverse stock split that occurred on March 13, 2026.

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Xilio Therapeutics, Inc.

(b) Address of issuer's principal executive offices:

828 Winter Street Suite 300 Waltham, MA 02451

Item 2.

Name of person filing:

(a) This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"): (i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); and (ii) Daniel Schneeberger ("Mr. Schneeberger").

(b) Address or principal business office or, if none, residence:

The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.

(c) Citizenship:

(i) ADAR1 Capital Management is a Texas limited liability company; and (ii) Mr. Schneeberger is a citizen of Switzerland.

(d) Title of class of securities:

Common Stock, par value $0.0001 per share

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☑ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☑ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the

Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) Amount beneficially owned:

The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.

(b) Percent of class:

The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.

(ii) Shared power to vote or to direct the vote:

The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.

(iii) Sole power to dispose or to direct the disposition of:

The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.

(iv) Shared power to dispose or to direct the disposition of:

The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E).

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ADAR1 Capital Management, LLC

Signature: /s/ Daniel Schneeberger
Name/Title: Daniel Schneeberger, Manager
Date: 11/16/2026

Daniel Schneeberger

Signature: /s/ Daniel Schneeberger
Name/Title: Daniel Schneeberger, in his individual capacity
Date: 11/16/2026

EXHIBIT A

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to shares of Common Stock, par value $0.0001 per share, of Xilio Therapeutics, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.

In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of November 16, 2026.

ADAR1 CAPITAL MANAGEMENT, LLC

/s/ Daniel Schneeberger
Daniel Schneeberger
Manager

/s/ Daniel Schneeberger
Daniel Schneeberger, in his individual capacity